Emyria Limited (ASX: EMD) has confirmed a $499,411 grant award from the Future Health Research and Innovation (FHRI) Seed Fund in partnership with the University of Western Australia (UWA).
The FHRI Seed Fund provides Western Australian innovators with non-dilutive funding to facilitate projects with high commercial potential. This grant will advance Emyria’s novel MDMA analogue drug discovery pipeline with UWA over the next 18 months to help validate our drug optimisation pipeline and potentially identify a drug candidate for development and commercialisation.
Grant funds will be allocated to key screening assays and gold-standard animal models delivered by global collaborators, including the National Institutes of Health (NIH), to progres towards clinical studies.
“We are thrilled to receive this substantial grant from the West Australian Department of Health in partnership with UWA. This brings the amount of non-dilutive funding won this year to over $500k creating a significant boost for Emyria’s long-term innovation pipeline and, along with our MDMA-assisted therapy evaluation program, helps reinforce our global leadership in MDMA-related treatment delivery and development,” CEO, Michael Winlo, said.
Emyria is dedicated to the development of new treatments for mental health, particularly to address major unmet needs in psychological trauma, and select neurological conditions. The company has established a unique operating model that delivers commercially viable clinical services and real patient impact in the short-term while fostering high potential innovation for long-term value.
Recently, the company established itself as one of the few clinical services, globally, with the expertise, bespoke facilities and regulatory approvals required to evaluate MDMA-assisted therapy for PTSD within the legal access pathways established by Australia’s Therapeutic Goods Administration (TGA).
Since 2021, Emyria and UWA have been creating and evaluating a library of proprietary MDMA-like compounds as part of the company’s long-term drug discovery and development initiatives, establishing Emyria as a global leader in MDMA-related treatments.
